GlassScriptPhysician profile
Victor W Chen
NPI 1417950668
$13,016.51
in general payments reported to CMS, 2019-2025
36 companies · $2,245 in 2025
The $2,245 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,718 · 2020: $2,263 · 2021: $1,289 · 2022: $1,392 · 2023: $1,939 · 2024: $2,171 · 2025: $2,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,135 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,134.81 |
| Education | $220.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,111.21 | 2019-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $2,020.96 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,377.27 | 2019-2025 | Krystexxa, Tavneos, Enbrel |
| Novartis Pharmaceuticals Corporation | $916.61 | 2019-2025 | |
| Janssen Biotech, INC. | $914.29 | 2019-2025 | Tremfya |
| Pfizer INC. | $848.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $686.89 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $458.69 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $387.67 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $318.55 | 2019-2025 | Benlysta, Shingrix, Arexvy |
| Horizon Therapeutics Plc | $293.19 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $254.35 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Mallinckrodt Hospital Products INC. | $243.47 | 2021-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.09 | 2019-2025 | Ofev |
| Sobi, INC | $153.33 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $121.84 | 2019 | |
| Organon LLC | $95.78 | 2023-2024 | Hadlima |
| Nevro Corp. | $68.21 | 2022 | |
| Pacira Therapeutics, INC. | $56.49 | 2019 | |
| Portola Pharmaceuticals, LLC | $48.30 | 2019 | |
| Celgene Corporation | $41.97 | 2019 | |
| Biotronik Nro, INC. | $41.58 | 2024-2025 | Prospera |
| Medexus Pharma, INC. | $36.66 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $35.83 | 2019-2025 | Tremfya, Xarelto |
| Sanofi-Aventis U.S. LLC | $35.62 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $35.55 | 2023-2024 | Strensiq |
| Mallinckrodt Enterprises LLC | $28.57 | 2019 | |
| Gilead Sciences, INC. | $26.36 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $23.33 | 2024 | Arcalyst |
| Biocon Biologics INC | $21.53 | 2024 | Hulio |
| Actelion Pharmaceuticals US, INC. | $20.71 | 2023 | Opsumit, Uptravi |
| Novo Nordisk INC | $18.69 | 2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $17.42 | 2019 | |
| Fidia Pharma USA INC. | $17.05 | 2020 | |
| Genentech USA, INC. | $13.26 | 2019 | |
| Smith+Nephew, INC. | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.